[Clinical presentation of tuberculosis in routine practice].

Area of Science:

• Rheumatology
• Infectious Diseases
• Clinical Medicine

Background:

• Biologic therapies have revolutionized rheumatic disease treatment but carry risks, including tuberculosis (TB).
• Established guidelines exist for TB screening and management in at-risk patients.
• Limited rheumatologist experience with TB due to its relative rarity in this population.

Observation:

• Analysis of TB cases (2006-2011) at a major rheumatology referral center.
• Focus on real-world data over a decade after biologics became widely used.
• Identified four cases illustrating diagnostic and therapeutic complexities.

Findings:

• Overt tuberculosis remains a potential life-threatening complication in patients receiving biologic treatment for rheumatic diseases.
• Case studies reveal significant difficulties in diagnosing and managing TB in this specific patient group.
• Real-world data provides insights beyond controlled clinical trials.

Implications:

• Highlights the persistent need for rigorous TB screening and monitoring protocols for rheumatic disease patients on biologics.
• Underscores the importance of continued education and experience-sharing among rheumatologists regarding TB management.
• Suggests potential gaps in current guidelines or their implementation in clinical practice.